213 related articles for article (PubMed ID: 27119370)
1. Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis.
Medvedeva EA; Berezin II; Surkova EA; Yaranov DM; Shchukin YV
Minerva Cardioangiol; 2016 Dec; 64(6):595-602. PubMed ID: 27119370
[TBL] [Abstract][Full Text] [Related]
2. [Galectin-3, Markers of Oxidative Stress and Renal Dysfunction in Patients With Chronic Heart Failure].
Medvedeva EA; Berezin II; Shchukin YV
Kardiologiia; 2017 Mar; 57(3):46-50. PubMed ID: 28762935
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
[TBL] [Abstract][Full Text] [Related]
4. Renal function largely influences Galectin-3 prognostic value in heart failure.
Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
[TBL] [Abstract][Full Text] [Related]
5. The relationship between galectin-3 levels and fragmented QRS (fQRS) in patients with heart failure with reduced left ventricular ejection fraction.
Barman HA; Durmaz E; Atici A; Kahyaoglu S; Asoglu R; Sahin I; Ikitimur B
Ann Noninvasive Electrocardiol; 2019 Nov; 24(6):e12671. PubMed ID: 31155816
[TBL] [Abstract][Full Text] [Related]
6. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of galectin-3 on admission in Chinese patients with heart failure: a prospective observational study.
Wang H; Chen Q; Li Y; Jing X; Liang T; Yang J
Acta Cardiol; 2017 Apr; 72(2):188-195. PubMed ID: 28597803
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
[TBL] [Abstract][Full Text] [Related]
10. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 is associated with severe heart failure and death: A hospital-based study in Chinese patients.
Wang N; Dang M; Zhang W; Lei Y; Liu Z
Scand J Immunol; 2020 May; 91(5):e12826. PubMed ID: 31514240
[TBL] [Abstract][Full Text] [Related]
12. Plasma galectin-3 as a biomarker for clinical staging of heart failure: a cross-sectional evaluation of 100 cases.
Gocer H; Günday M; Ünal M
Clin Ter; 2019; 170(4):e267-e271. PubMed ID: 31304514
[TBL] [Abstract][Full Text] [Related]
13. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
[TBL] [Abstract][Full Text] [Related]
14. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure.
Jungbauer CG; Riedlinger J; Block D; Stadler S; Birner C; Buesing M; König W; Riegger G; Maier L; Luchner A
Biomark Med; 2014; 8(6):777-89. PubMed ID: 25224934
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure.
Lala RI; Lungeanu D; Darabantiu D; Pilat L; Puschita M
Herz; 2018 Mar; 43(2):146-155. PubMed ID: 28235980
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
[TBL] [Abstract][Full Text] [Related]
17. Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction.
Kanagala P; Arnold JR; Khan JN; Singh A; Gulsin GS; Chan DCS; Cheng ASH; Yang J; Li Z; Gupta P; Squire IB; McCann GP; Ng LL
Biomarkers; 2020 Nov; 25(7):556-565. PubMed ID: 32803990
[TBL] [Abstract][Full Text] [Related]
18. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
van der Velde AR; Gullestad L; Ueland T; Aukrust P; Guo Y; Adourian A; Muntendam P; van Veldhuisen DJ; de Boer RA
Circ Heart Fail; 2013 Mar; 6(2):219-26. PubMed ID: 23395934
[TBL] [Abstract][Full Text] [Related]
20. The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation.
Franeková J; Hošková L; Sečník P; Pazderník M; Kotrbatá M; Kubíček Z; Jabor A
Clin Chem Lab Med; 2016 Feb; 54(2):339-44. PubMed ID: 26351922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
